Adalimumab is a TNF-α inhibitor used in clinical practice in the treatment of many diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), and juvenile idiopathic arthritis [21]. The gene discussed is TNF; the disease is inflammatory bowel disease.